Sivik Global Healthcare’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Sivik Global Healthcare’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-32,802	Closed	-$874K	–	63
2018 Q3	$874K	Buy	32,802 +17,802	+119%	+$581K	0.31%	59
2018 Q2	$567K	Buy	+15,000	New	+$574K	0.22%	61
2018 Q1	–	Sell	-40,000	Closed	-$1.95M	–	72
2017 Q4	$1.95M	Buy	40,000 +15,000	+60%	+$759K	0.72%	60
2017 Q3	$1.35M	Sell	25,000 -5,000	-17%	-$294K	0.46%	67
2017 Q2	$1.69M	Buy	+30,000	New	+$1.2M	0.62%	56
2016 Q1	–	Sell	-22,500	Closed	-$1.16M	–	68
2015 Q4	$1.16M	Sell	22,500 -7,500	-25%	-$364K	0.55%	56
2015 Q3	$1.28M	Hold	30,000	–	–	0.62%	52
2015 Q2	$1.37M	Buy	30,000 +5,000	+20%	+$201K	0.47%	60
2015 Q1	$949K	Buy	+25,000	New	+$859K	0.32%	74
2014 Q2	–	Sell	-30,600	Closed	-$793K	–	81
2014 Q1	$793K	Buy	30,600 +5,600	+22%	+$149K	0.5%	64
2013 Q4	$644K	Buy	+25,000	New	+$608K	0.46%	55

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Sivik Global Healthcare's PTLA Position: Q4 2018 in Review

Sivik Global Healthcare sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 32,802 shares — an estimated $874K sold.

Sivik Global Healthcare first reported a position in PTLA in Q4 2013 and held it in 11 quarters. The position peaked at $1.95M in Q4 2017. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

Sivik Global Healthcare reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Sivik Global Healthcare sold 32,802 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $874K.
Sivik Global Healthcare first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 11 quarters.
Sivik Global Healthcare's Portola Pharmaceuticals, Inc. position peaked at $1.95M in Q4 2017.
181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on Sivik Global Healthcare's 13F filing for Q4 2018, filed 12 Feb 2019.